Effect of regional citrate anticoagulation on thrombogenicity and biocompatibility during CVVHDF

Renal Failure

Volumn 28, Issue 2, 2006, Pages 107-118

  Polanská, Kamila ^a   Opatrný Jr , Karel ^a,b   Rokyta Jr , Richard ^a   Kroužecký, Aleš ^a   Vit, Ladislav ^a   Kasal, Eduard ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Acute renal failure; Citrate; Continuous hemodiafiltration; Critically ill; Heparin; Thrombogenicity

Indexed keywords

BETA THROMBOGLOBULIN; CALCIUM; CITRATE TRISODIUM; D DIMER; HEPARIN; POLYACRYLONITRILE; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLEEDING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HEMOSTASIS; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOGENICITY;

AGED; ANTICOAGULANTS; CITRATES; HEMODIAFILTRATION; HEPARIN; HUMANS; KIDNEY FAILURE, ACUTE; THROMBOSIS;

EID: 33645547305     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220500530338     Document Type: Article

References (39)

1. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int. 2002;62:1855-1863.
2. Ronco C, Zanella M, Brendolan A. Management of severe acute renal failure in critically ill patients: an international survey in 345 centres. Nephrol Dial Transplant. 2001;16:230-237.
3. Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis. 1998;2:185-207.
4. Reeves JH, Graan M. Randomized controlled trial enoxaparin versus heparin in continuous renal replacement therapy. Blood Purif. 2003;21:183-207.
5. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron. 1994;66(4):431-437.
6. Schneider T, Heuer B, Deller A, Boesken WH. Continuous hemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II). Wien Klin Wochenschr. 2000;112(12):552-555.
7. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991;93:215-217.
8. Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous hemodiafiltration using commercial solutions. Nephrol Dial Transplant. 2004;19:171-178.
9. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001;60:370-374.
10. Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol. 2004;61(2):134-143.
11. Kutsogiannis JD, Mayers I, Nin Chin WD, Gibney N. Regional citrate anticoagulatinon in continuous venovenous hemodiafiltration. Am J Kidney Dis. 2000;35:802-811.
12. Zemanová P, Opatrný K Jr, Polanská K, et al. Is it appropriate to tune regional citrate anticoagulation during hemodialysis by ionized calcium levels? Blood Purif. 2005;23:407.
13. Opatrný K Jr, Polanská K, Kroužecký A, Vít L, Novák I, Kasal E. The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration. Int J Artif Organs. 2002;25(6):520-528.
14. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M. Continuous venovenous hemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med. 1997;23:38-43.
15. Stefanidis I, Hagel J, Kierdorf H, Maurin N. Influencing hemostasis during continuous venovenous hemofiltration after acute renal failure: comparison with intermittent hemodialysis. Contrib Nephrol. 1995;116:140-144.
16. Cardigan RA, McGloin H, Mackie IJ, Machin J, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int. 1999;55:1568-1574.
17. Cheung AK, Faezi-Jenkin B, Leypoldt JK. Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol. 1994;5(1):110-115.
18. Tayama E, Hayashida N, Akasu K, et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Int J Artif Organs. 2000;24:618-623.
19. Bos JC, Grooteman MPC, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant. 1997;12:1387-1393.
20. Plötz FB, van Oeveren W, Hultquist KA, Miller C, Bartlett RH, Wildevuur CRH. A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Int J Artif Organs. 1992;16:366-370.
21. Schrefl A, Kellner K-H, Hartmann J, Strobl W, Falkenhagen D. A novel monitor for anticoagulation with citrate. Int J Artif Organs. 2001;24:535.
22. Charney DI, Salmond R. Cardiac arrest after hypertonic citrate anticoagulation for chronic hemodialysis. ASAIO Trans. 1990;36:M217-M219.
23. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976-981.
24. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260-265.
25. Kutsogiannis DJ, Gibney RTN, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67:2361-2367.
26. Tobe SW, Aujla P, Walele AA, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care. 2003;18:121-129.
27. Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med. 2002;28:1419-1425.
28. Opatrný K Jr, Vít L, Opatrná S, et al. Hemocompatibility in hemodialysis and erythropoietin therapy. Artif Organs. 1995;19(8):814-820.
29. Frank RD, Weber J, Dresbach H, Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int. 2001;60:1972-1981.
30. Ivanovich P, Hammerschmidt DE, Quintanilla A, et al. Behaviour of platelets and beta-thromboglobulin. Nephrol Dial Transplant. 1993;8(suppl 2):15-19.
31. Silvester W, Honoré P, Sieffert E, et al. Interleukins 6 and 8, tumour necrosis factor alpha and complement D clearance by polyacrylonitrile and polysulphone membranes during hemofiltration in critically ill patients. Presented at: Continuous Hemofiltration in Intensive Care Meeting; Paris; 1996.
32. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7:145-150.
33. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol. 1996;7:234-241.
34. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favourable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol. 2004;17:819-825.
35. Wiegmann TB, McDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis. 1988;11:418-424.
36. Wegmuller E, Montandon A, Nydegger U, Descoeudres C. Biocompatibility of different hemodialysis membranes: activation of complement and leukopenia. Int J Artif Organs. 1986;9:85-92.
37. Cheung AK, Parker CJ, Wilcox LA, Janatova J. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophan. Kidney Int. 1990;37:1055-1059.
38. Hoenich NA, Woffindin C, Brennan A, Cox PJ, Matthews JN, Goldfinch M. A comparison of three brands of polysulfone membranes. J Am Soc Nephrol. 1996;7:871-876.
39. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis. 1997;30(5, suppl. 4):S20-S27.